Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Pharm ; 565: 108-122, 2019 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-31071417

RESUMEN

Vismodegib (Erivedge®, Genentech) is a first-in-class inhibitor of the hedgehog signaling pathway for the treatment of basal cell carcinoma (BCC). The treatment currently consists of the oral administration of Erivedge® capsules. Although it has shown therapeutic efficacy in clinical trials, there are many side effects related to its systemic distribution. In this work, we have incorporated vismodegib to ultradeformable liposomes in order to obtain a nano-drug delivery system via topical route, which could be useful to reduce systemic distribution -and consequently side effects- while achieving a viable epidermis-specific target where neoplastic events of BCC develop. Vismodegib was loaded into liposomes composed of soy phosphatidylcholine and sodium cholate, and the obtained formulation was characterized by different techniques, both experimental and computational. Several analyses were performed,with a special focus on the interaction of the drug with the liposomal membrane. Additionally, the penetration of Vismodegib delivered by ultradeformable liposomes was assessed on human skin explants. This is one of the first works that propose the topical route for Vismodegib and the first, to our knowledge, in stabilizing this active into a nano-drug delivery system specifically designed for penetrating the stratum corneum impermeable barrier.


Asunto(s)
Anilidas/administración & dosificación , Antineoplásicos/administración & dosificación , Nanoestructuras/administración & dosificación , Piridinas/administración & dosificación , Piel/metabolismo , Administración Tópica , Adulto , Femenino , Humanos , Liposomas , Absorción Cutánea , Neoplasias Cutáneas/tratamiento farmacológico
2.
Sci Rep ; 9(1): 300, 2019 01 22.
Artículo en Inglés | MEDLINE | ID: mdl-30670733

RESUMEN

The mouse Major Urinary Proteins (MUPs) contain a conserved ß-barrel structure with a characteristic central hydrophobic pocket that binds a variety of volatile compounds. After release of urine, these molecules are slowly emitted in the environment where they play an important role in chemical communication. MUPs are highly polymorphic and conformationally stable. They may be of interest in the construction of biosensor arrays capable of detection of a broad range of analytes. In this work, 14 critical amino acids in the binding pocket involved in ligand interactions were identified in MUP20 using in silico techniques and 7 MUP20 mutants were synthesised and characterised to produce a set of proteins with diverse ligand binding profiles to structurally different ligands. A single amino acid substitution in the binding pocket can dramatically change the MUPs binding affinity and ligand specificity. These results have great potential for the design of new biosensor and gas-sensor recognition elements.


Asunto(s)
Sitios de Unión/genética , Mutación Puntual , Proteínas/genética , Aminoácidos , Animales , Péptidos y Proteínas de Señalización Intercelular , Ligandos , Ratones , Proteínas Mutantes/síntesis química , Proteínas Mutantes/genética , Unión Proteica/genética , Proteínas/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA